IMR Press / RCM / Volume 9 / Issue 2 / pii/1560999976781-2092001038

Reviews in Cardiovascular Medicine (RCM) is published by IMR Press from Volume 19 Issue 1 (2018). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by IMR Press on as a courtesy and upon agreement with MedReviews, LLC.

Open Access Review
Appropriate Dose Transition to a Controlled-Release Formulation of Carvedilol in Patients With Hypertension
Show Less
1 Hypertensive Diseases Unit, Section of Endocrinology, Diabetes, and Metabolism, University of Chicago Pritzker School of Medicine, Chicago, IL
2 Department of Medicine, State University of New York Downstate College of Medicine, New York, NY
Rev. Cardiovasc. Med. 2008, 9(2), 96–105;
Published: 30 June 2008
Few patients with hypertension meet recommended target blood pressure goals, and most hypertensive patients require at least 2 antihypertensive medications from different pharmacologic classes to adequately lower blood pressure. β-Blockers are guideline-recommended for the treatment of hypertension with compelling indications. β-Blockers differ with respect to pharmacology (particularly receptor biology and ancillary properties), hemodynamic effects, and tolerability. In clinical practice, the choice of β-blockers for individual patients with hypertension is often based on practical issues such as convenience and cost. However, given the pharmacologic and clinical trial data demon strating differences, the choice of β-blocker for the treatment of high-risk hypertension should be evidence-based. Vasodilating β-blockers, such as carvedilol, decrease blood pressure without the concerning hemodynamic, renal, and metabolic responses associated with most β-blockers. The use of carvedilol CR (once daily) may be preferable to a twice-daily regimen.
Carvedilol CR
Back to top